Melanoma

Inclusion Criteria

- Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal) metastatic melanoma who had received at least one but no more than two previous systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who had not responded to or who had progressed after their most recent therapy were eligible for enrollment
 - Presence of at least one lesion fulfilling the minimum Response Evaluation Criteria in Solid Tumors (RECIST) size requirements for a target lesion - Use of highly effective birth control methods in females of child-bearing potential
 - Able to undergo either contrast enhanced computed tomography (CT) scan or contrast enhanced magnetic resonance imaging (MRI) scan for tumor assessment
 - Life expectancy greater than 3 months
 - Adequate organ and bone marrow functions as defined below: absolute neutrophil count  ≥ 1500 /µL, platelets ≥ 100,000 /µL, creatinine ≤ 1.5 × upper limit of normal (ULN) or measured creatinine clearance of ≥ 60 mL/min x 1.73 m2 body surface area, total bilirubin ≤ 1.5 times ULN, aspartate aminotransferase or serum glutamic oxalacetic transaminase/alanine aminotransferase or serum glutamic pyruvic transaminase∗ ≤ 2.5 times ULN
 - Negative serum pregnancy test within 2 weeks prior to receiving the first dose of study drug in female subjects of childbearing potential. Agreement to use a highly effective method of birth control throughout the study period and 3 months thereafter for sexually active males and females of childbearing potentia

Exclusion Criteria

- Active malignancy in the last five years
 - Pregnancy, breast feeding
 - HIV infection
 - Brain metastasis
 - Concomitant use of corticosteroids or valproic acid
 - Uncontrolled intercurrent illness
 - Diagnosis of uveal melanoma
 - Eastern Cooperative Oncology Group  performance status ≥ 2
 - Ongoing effects from previous investigational drug studies or concomitant 
participation in other investigational drug studies
 - Prior use of MS-275 or any other HDAC inhibitor
 - History of allergic reactions attributed to compounds of similar chemical or biologic composition to MS-275
 - Anticancer therapy
 - Active gastrointestinal conditions that might predispose for poor drug absorption
 - Major surgery within 4 weeks prior to enrollment
 -  Hypophosphatemia < 2.5 mg/dL at screening, if not corrected in the screening period
 -  Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study